New York, June 7, 2024 - PRISM MarketView - Shares in Vanda Pharmaceuticals (Nasdaq: VNDA) soared on Thursday after the company confirmed that it had received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the company for $8.00 per share in cash.
Vanda stated that its Board of Directors is consulting with independent financial and legal advisors and will carefully review and evaluate the indication of interest to determine the course of action that is in the best interests of Vanda and its shareholders.
The company is focused on the development and commercialization of therapies for central nervous system disorders, including sleep disorders, schizophrenia, and other neurological conditions. Vanda developed and is commercializing Fanapt (iloperidone), which is approved for the treatment of schizophrenia. Vanda is also involved in researching treatments for mood disorders, movement disorders, and other neurological conditions.
The company presented at SLEEP 2024 this week.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities